Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58Leukemia 52Lymphoma 37Myelodysplastic Syndromes 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 22Hodgkin Disease 22Leukemia, Myeloid, Acute 18Multiple Myeloma 17Myeloproliferative Disorders 14Recurrence 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, T-Cell, Peripheral 10Lymphoma, Follicular 10Congenital Abnormalities 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Hematologic Neoplasms 9Burkitt Lymphoma 9Anemia, Aplastic 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Graft vs Host Disease 7Sezary Syndrome 6Primary Myelofibrosis 6

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4venetoclax 3ruxolitinib 3Cytarabine 3Alemtuzumab 3itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1ibrutinib 1Tacrolimus 1Sensitivity and Specificity 1Mitoxantrone 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × Alemtuzumab × Clear all
NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

German CLL Study Group

Phase 2 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡